FDA approves Aimovig as first CGRP inhibitor for migraines

FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late Thursday to prevent migraine in adults. The drug is the first calcitonin gene-related

Read the full 275 word article

User Sign In